Second-line treatment after CDK4/6 inhibitors in hormone receptor positive metastatic breast cancer: What is the role of capecitabine?

IF 3.2 3区医学 Q2 ONCOLOGY

Clinical oncology Pub Date : 2025-02-01 DOI:10.1016/j.clon.2024.103719

R. Mawella, C. Peters, A. Moss, R. Simcock, D. Bloomfield, G. Bertelli

引用次数: 0

查看原文本刊更多论文

激素受体阳性转移性乳腺癌CDK4/6抑制剂后的二线治疗：卡培他滨的作用是什么？

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical oncology 医学-肿瘤学

CiteScore

5.20

自引率

8.80%

发文量

332

审稿时长

40 days

期刊介绍： Clinical Oncology is an International cancer journal covering all aspects of the clinical management of cancer patients, reflecting a multidisciplinary approach to therapy. Papers, editorials and reviews are published on all types of malignant disease embracing, pathology, diagnosis and treatment, including radiotherapy, chemotherapy, surgery, combined modality treatment and palliative care. Research and review papers covering epidemiology, radiobiology, radiation physics, tumour biology, and immunology are also published, together with letters to the editor, case reports and book reviews.